This practice poses a problem because pharmacovigilance is a team sport. Patients, patient support programs, local representatives of a life science organization, healthcare providers and pharmacovigilance physicians are all needed to contribute to and review an adverse event report before it gets sent to a government regulatory agency. It is critical to gather and understand these insights before reporting is underway.
Beyond this workflow challenge, organizations often face a problem of scalab…